SCHEMBL3240602

SCHEMBL3240602

Cc1c(F)cccc1C(=O)NC(c1ccccc1)C(C)(C)N1CCCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 2/20 0.41
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
TAS1R2 Q8TE23 1/20 0.40
ALDH1A1 P00352 6/20 0.38
NPC1 O15118 4/20 0.38
RAB9A P51151 3/20 0.38
KDM4E B2RXH2 3/20 0.38
HTT P42858 2/20 0.38
ATM Q13315 2/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
KLRK1 P26718 1/20 0.36
MICA Q29983 1/20 0.36
RAET1L Q5VY80 1/20 0.36
MAPT P10636 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
POLB P06746 1/20 0.36
TP53 P04637 1/20 0.36
MCL1 Q07820 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3240030 0.91 LMNA (0.36) SLC6A9ALDH1A1NPC1RAB9AKDM4E
SCHEMBL3236014 0.88 SLC6A9 (0.47) SLC6A9ALDH1A1
SCHEMBL3230685 0.87 ALDH1A1 (0.44) SLC6A9TAS1R3TAS1R1TAS1R2ALDH1A1
SCHEMBL8266491 0.87 SLC6A9 (0.37) SLC6A9ALDH1A1NPC1KDM4EHTT
SCHEMBL3241918 0.87 ALDH1A1 (0.43) SLC6A9ALDH1A1NPC1KDM4EHTT
SCHEMBL3238470 0.82 SLC6A9 (0.46) SLC6A9TAS1R3TAS1R1TAS1R2ALDH1A1
SCHEMBL3239409 0.81 KLRK1 (0.46) ALDH1A1KMT2AMEN1KLRK1MICA
SCHEMBL3238315 0.81 ALDH1A1 (0.41) TAS1R3TAS1R1ALDH1A1NPC1KDM4E
SCHEMBL3238049 0.81 ITGA4 (0.49) SLC6A9NPC1KMT2AMEN1LMNA
SCHEMBL3243734 0.80 SLC6A9 (0.48) SLC6A9ALDH1A1NPC1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287547-A1 Glycine Transport Inhibitors SLC18A2, SLC6A5, SLC1A2 SLC6A9 13/4885TAS1R3 3167/4885TAS1R1 2565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.